Merrimack Pharmaceuticals (NASDAQ: MACK) is one of 188 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Merrimack Pharmaceuticals to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.
This table compares Merrimack Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merrimack Pharmaceuticals Competitors||-4,557.58%||-472.07%||-42.45%|
Institutional and Insider Ownership
50.1% of Merrimack Pharmaceuticals shares are held by institutional investors. Comparatively, 49.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 8.5% of Merrimack Pharmaceuticals shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Merrimack Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Merrimack Pharmaceuticals||$144.27 million||-$151.74 million||-1.46|
|Merrimack Pharmaceuticals Competitors||$217.40 million||-$39.53 million||-59.46|
Merrimack Pharmaceuticals’ competitors have higher revenue and earnings than Merrimack Pharmaceuticals. Merrimack Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations and price targets for Merrimack Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merrimack Pharmaceuticals Competitors||556||2506||6734||131||2.65|
Merrimack Pharmaceuticals presently has a consensus target price of $15.00, indicating a potential upside of 40.85%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.41%. Given Merrimack Pharmaceuticals’ higher possible upside, equities research analysts plainly believe Merrimack Pharmaceuticals is more favorable than its competitors.
Volatility and Risk
Merrimack Pharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals’ competitors have a beta of 1.51, meaning that their average share price is 51% more volatile than the S&P 500.
Merrimack Pharmaceuticals competitors beat Merrimack Pharmaceuticals on 7 of the 13 factors compared.
About Merrimack Pharmaceuticals
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.